Article | November 22, 2021

Scalable AAV Purification Process For Gene Therapy

Source: Cytiva
iStock-1256322438-lab-research-scientist

Processes to produce a common viral vector for gene therapy – adeno-associated virus (AAV) – are in place, but there’s room to improve them. Here we focus on optimizing AAV purification to achieve high overall yields and efficiently remove empty capsids and other impurities.

We developed a purification process for AAV2 and AAV5 serotypes, based on scalable, cost-efficient, and robust filtration and chromatography-based processes. The steps include harvest by cell lysis, clarification, concentration and buffer exchange, affinity capture, and finally anion exchange polishing to reduce empty capsids.

Further, we developed a convenient Biacore™ surface plasmon resonance (SPR) assay for robust and accurate determination of AAV2 titer.

Read this article to see the results.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online